You searched for sprycel - MPR

Your search for sprycel returned 18 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for sprycel returned 18 results

Sort Results:

Relevant Recent
Drug Monograph


Dasatinib 20mg, 50mg, 70mg, 80mg, 100mg, 140mg; tabs.

New Follow-Up Data for Sprycel Among the Longest for CML

The labeling for Sprycel (dasatinib; Bristol-Myers Squibb and Otsuka) has been updated with new three-year efficacy and safety data in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase and five-year data in CP Ph+ CML patients who are resistant or intolerant to Gleevec (imatinib mesylate; Novartis).

Sprycel receives full approval for chronic myeloid leukemia

The FDA has granted full approval for Sprycel (dasatinib tablets, from Bristol-Myers Squibb), an oral tyrosine kinase inhibitor, for the treatment of adults in all phases of chronic myeloid leukemia (CML) (ie, chronic, accelerated, myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy, including Gleevec (imatinib mesylate, from Novartis).